Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease

Seung Hun Lee, Mi Jung Kim, Beom Jun Kim, Sung Reul Kim, Sail Chun, Jin Sook Ryu, Ghi Su Kim, Myoung Chong Lee, Jung Min Koh, Sun Ju Chung

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)


We investigated whether homocysteine (Hcy)-lowering therapy or an antioxidant prevented bone loss in Parkinson's disease (PD) patients taking levodopa. Forty-two PD patients with low bone mineral density (BMD) taking levodopa were randomly assigned to Hcy-lowering therapy (5 mg folate and 1500 μg vitamin B12 daily), α-lipoic acid (α-LA) therapy (1200 mg daily), or control groups. Primary outcomes were BMD changes from baseline to 12 months. Secondary outcomes were changes in Hcy level, and C-telopeptide (CTX) levels at 12 months. Forty-one patients completed the study. Hcy-lowering therapy resulted in significantly greater BMD changes at the lumbar spine (4.4%), total femur (2.8%), and femur shaft (2.8%) than control (P = 0.005-0.023). BMD changes in the α-LA therapy group were similar to those of the control group, but changes at the trochanter (4.6%) were significantly greater in the α-LA therapy group than in the control group after adjustment for body mass index changes. Hcy concentrations decreased to 35.2% ± 13.4% in the Hcy-lowering therapy group, but increased in other groups. Serum CTX levels at 12 months tended to be lower in the Hcy-lowering group (0.442 ± 0.024 ng/mL) than control group (0.628 ± 0.039 ng/mL) (P = 0.159). This small trial suggests that Hcy-lowering therapy may prevent bone loss in PD patients taking levodopa.

Original languageEnglish
Pages (from-to)332-340
Number of pages9
JournalMovement Disorders
Issue number3
Publication statusPublished - 2010 Feb 15
Externally publishedYes


  • Folate
  • Homocysteine
  • Osteoporosis
  • Parkinson's disease
  • Vitamin B

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease'. Together they form a unique fingerprint.

Cite this